Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HM 15275

Next Previous
X
Search
Drug Profile

HM 15275

Alternative Names: HM-15275

Latest Information Update: 29 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Obesity therapies
  • Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Obesity
  • Preclinical Heart failure

Most Recent Events

  • 21 Jun 2024 Preclinical trials in Heart failure in USA (unspecified route), prior to June 2024
  • 21 Jun 2024 Pharmacodynamics data from a preclinical studies in Heart failure presented at 84th Annual Scientific Sessions of the American Diabetes Association (ADA-2024)
  • 31 May 2024 Hanmi Pharmaceutical submits Investigational New Drug (IND) application for a phase I trial in Obesity, before May 2024 (Hanmi Pharmaceutical pipeline, July 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top